Methyl-dihydro-(2H)-pyran-2-one | 63127-54-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: Methyl-dihydro-(2H)-pyran-2-one
• 英文别名: methyl-dihydro-pyranone；3-methyl-3,4-dihydropyran-2-one
• CAS: 63127-54-8
• 化学式: C₆H₈O₂
• 分子量: 112.128
• InChiKey: VKXQOHIRQZRZAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Methyl-dihydro-(2H)-pyran-2-one 、 甲醇 生成 methyl 2-methyl-5-oxopentanoate
  参考文献：
  名称：

  SCHEEREN J. W.; BAKKER C. G.; PEPERZAK R.; NIVARD R. J. F., TETRAHEDRON LETT., 28,(1987) N 16, 1821-1824

  摘要：

  DOI：
• 作为产物：
  描述：

  (1-oxo-2-propenyl)trimethylsilane 在 氰化四丁基铵 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以58%的产率得到Methyl-dihydro-(2H)-pyran-2-one
  参考文献：
  名称：

  degl'Innocenti, Alessandro; Ricci, Alfredo; Mordini, Alessandro, Gazzetta Chimica Italiana, 1987, vol. 117, # 11, p. 645 - 648

  摘要：

  DOI：

文献信息

• Mechanistic and synthetic aspects of the acid-catalysed hydrolysis of 2,2-dimethoxy-3,4-dihydropyrans into 3,4-dihydro-α-pyrones and δ-keto esters
  作者：J.W. Scheeren、C.G. Bakker、R. Peperzak、R.J.F. Nivard

  DOI：10.1016/s0040-4039(00)95431-5

  日期：1987.1

  Acid-catalysed hydrolysis of 2,2-dimethoxy-3,4-dihydropyrans () yields mixtures of δ-keto esters () and 3,4-dihydro-α-pyrones (). The amount of increases with increasing alkyl substitution in the 3-, 5- and 6-position of and when the hydrolysis is carried out in a two-phases system of water/dichloromethane. It is shown that is formed directly from whereas is formed directly from and by methanolysis

  酸催化的2,2-二甲氧基-3,4-二氢吡喃（）水解生成δ-酮酸酯（）和3,4-二氢-α-吡喃酮（）的混合物。当在水/二氯甲烷的两相系统中进行水解时，随着在3位，5位和6位烷基的取代增加而增加的量。结果表明，甲醇直接由形成，而甲醇则由甲醇直接形成。讨论了这些水解反应的机理和合成方面。
• PLOUIN D.; BEAUME-COEUR C.; GLENAT R., C. R. ACAD. SCI., 1977, C284, NO 8, 343-346
  作者：PLOUIN D.、 BEAUME-COEUR C.、 GLENAT R.

  DOI：——

  日期：——
• INNOCENTI, ALESSANDRO DEGL;RICCI, ALFREDO;MORDINI, ALESSANDRO;REGINATO, G+, GAZZ. CHIM. ITAL, 117,(1987) N 11, 645-648
  作者：INNOCENTI, ALESSANDRO DEGL、RICCI, ALFREDO、MORDINI, ALESSANDRO、REGINATO, G+

  DOI：——

  日期：——
• COMPOSITIONS AND METHODS FOR TREATING CANCER AND DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20160015709A1

  公开（公告）日：2016-01-21

  In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing Growth Factor Inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a Growth Factor inhibitor on a cell, or, a method for re-sensitizing a cell to a Growth Factor Inhibitor, comprising for example, administration of a combination of a TBK1 inhibitor and an RTK inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell. In alternative embodiments, the invention provides compositions and methods for determining: whether an individual or a patient would benefit from or respond to administration of a Growth Factor Inhibitor, or, which individuals or patients would benefit from a combinatorial approach comprising administration of a combination of: at least one growth factor and at least one compound, composition or formulation used to practice a method of the invention, such as an NFKB inhibitor, such as a lenalidomide or a REVLIMID™, or IKK inhibitor; or an inhibitor of Galectin-3.
• COMPOSITIONS FOR DETECTING CIRCULATING INTEGRIN BETA-3 BIOMARKER AND METHODS FOR DETECTING CANCERS AND ASSESSING TUMOR PRESENCE OR PROGRESSION, CANCER DRUG RESISTANCE AND TUMOR STEMNESS
  申请人：The Regents of the University of California

  公开号：US20180203014A1

  公开（公告）日：2018-07-19

  Provided are compositions, including kits, and methods comprising use of a biomarker β 3 integrin, including the α v β 3 integrin, for detecting circulating tumor cells (CTCs), tumor stem cells, extracellular vesicles (EV), including exosomes and microvesicles, that are released by CTCs or cancer cells, as well as the tumor from which the CTCs or EVs derive, and to make a patient prognosis, and to assess tumor progression, and drug resistance (for example, resistance to tyrosine kinase inhibitors), e.g., for several cancers including: breast, colon, lung and pancreatic cancers. In alternative embodiments, a patient fluid sample, e.g., a blood, serum, urine, CSF or other sample, is taken and used to detect cancer stem cells, EVs- and/or CTCs-comprising β 3 integrin and/or a α v β 3 integrin. Provided are compositions, including kits, and methods and uses of the biomarker β 3 integrin for anti-cancer drug design. In alternative embodiments, applications of compositions, including kits, and methods and uses as provided herein include conjugation of an imaging or therapeutic agent to an antibody targeting integrin β 3 for detection and/or targeted destruction of integrin β 3 expressing cancer stem cells and/or CTCs.